Details of the Drug

General Information of Drug (ID: DM3ZNY0)

Drug Name
KI-0502
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 3 [1]
Cross-matching ID
TTD ID
D09LIZ

References

1 A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. Eur J Cancer. 2015 Mar;51(4):522-32.